Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Soberano

Pediatrics St Augustine, FL Medical Doctor

NPI 1477596377 CMS profile 111897

493 Prosperity Lake Dr, St Augustine, FL 32092

Open in the dashboard

General payments

$2,734

153 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Soberano of St Augustine, FL is reported in the CMS Open Payments database as having received $2,734 across 153 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $394 22
2024 General $578 29
2023 General $136 7
2022 General $307 13
2021 General $624 42
2020 General $315 17
2019 General $380 23

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Soberano
  • Pediatrics median
  • Middle half of Pediatrics
  • National median

In program year 2025, general payments to Michael Soberano were reported at $394. Among 22,296 Pediatrics profiles paid that year, the median was $97 and the middle half received between $37 and $210.

Show as a table
Year Michael Soberano Pediatrics median Middle half National median
2019 $380 $86 $31–$183 $163
2020 $315 $49 $22–$110 $114
2021 $624 $68 $27–$158 $132
2022 $307 $77 $30–$173 $149
2023 $136 $88 $33–$190 $160
2024 $578 $94 $34–$206 $164
2025 $394 $97 $37–$210 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Ironshore Pharmaceuticals Inc. $426 21 payments
  2. Corium, Inc. $366 18 payments
  3. Neos Therapeutics, LP $311 29 payments
  4. Collegium Pharmaceutical, Inc. $272 14 payments
  5. Tris Pharma Inc $256 11 payments
  6. GlaxoSmithKline, LLC. $249 10 payments
  7. Merck Sharp & Dohme Corporation $140 8 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $128 7 payments
  9. kaleo, Inc. $94 5 payments
  10. Adlon Therapeutics L.P. $73 4 payments
  11. Other $419 26 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,734 153 payments
Products named General payments · program years 2019–2025
  1. JORNAY PM Central Nervous System Stimulant $386 19 payments
  2. Azstarys $366 18 payments
  3. Jornay PM Adhd $272 14 payments
  4. COTEMPLA XR-ODT $251 19 payments
  5. BEXSERO $249 10 payments
  6. VYVANSE $148 8 payments
  7. Dyanavel XR $112 6 payments
  8. GARDASIL 9 $111 6 payments
  9. Adzenys XR-ODT Adhd $110 7 payments
  10. Adzenys XR-ODT Adhd $103 16 payments
  11. Other $1,277 73 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

153 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record